Comparative Pharmacology
Head-to-head clinical analysis: POLMON versus THEOCLEAR 100.
Peer-Reviewed Evidence
Head-to-head clinical analysis: POLMON versus THEOCLEAR 100.
POLMON vs THEOCLEAR-100
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Polmon (polymyxin B) is a cationic polypeptide antibiotic that disrupts bacterial cell membrane integrity by binding to lipopolysaccharides and phospholipids in the outer membrane, increasing permeability and causing cell death.
Theophylline relaxes bronchial smooth muscle by inhibiting phosphodiesterase, increasing intracellular cAMP, and antagonizing adenosine receptors.
1-2 mg intravenously every 2-4 hours as needed; maximum 8 mg/day.
100 mg orally every 6 hours; adjust based on serum theophylline concentrations and clinical response (target 5-15 mcg/mL).
None Documented
None Documented
Terminal elimination half-life is 12-18 hours in healthy adults; prolonged to 24-36 hours in severe hepatic impairment requiring dose adjustment.
Terminal elimination half-life is approximately 8-12 hours in healthy adults. In smokers, half-life is reduced by 50%; in patients with hepatic cirrhosis or heart failure, half-life is prolonged to 24-36 hours.
Renal excretion of unchanged drug accounts for 40-50% of elimination; biliary/fecal excretion accounts for 50-60%.
Renal excretion accounts for approximately 10% of the administered dose as unchanged drug. The remainder is hepatically metabolized, with metabolites excreted renally. Biliary/fecal elimination is negligible (<5%).
Category C
Category C
Bronchodilator
Bronchodilator